

**Eucrisa (crisaborole)  
Effective 10/01/2021**

<b>Plan</b>	<input type="checkbox"/> MassHealth <input checked="" type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization <input checked="" type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Benefit</b>	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		
<b>Specialty Limitations</b>	N/A		
<b>Contact Information</b>	<b>Specialty Medications</b>		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	<b>Non-Specialty Medications</b>		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	<b>Medical Specialty Medications (NLX)</b>		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
<b>Exceptions</b>	N/A		

### Overview

Crisaborole is a topical phosphodiesterase-4 (PDE-4) inhibitor indicated for treatment of mild to moderate atopic dermatitis in adults and pediatric patients at least 3 months of age.

### Coverage Guidelines

Authorization may be granted for members new to AllWays Health Partners who are currently receiving treatment with Eucrisa excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

### OR

Authorization may be granted for members when ALL the following criteria are met, and documentation is provided:

1. The member is diagnosed with mild to moderate atopic dermatitis
2. The member is at least 3 months old
3. The member meets ONE of the following:
  - a. The member has experienced an inadequate response or intolerance to a medium or higher potency topical corticosteroid or a topical calcineurin inhibitor
  - b. The member has a contraindication to both topical corticosteroids and topical calcineurin inhibitors

### Continuation of Therapy

Reauthorization requires physician documentation of improvement of member’s condition.

### Limitations

1. Initial approvals and reauthorizations will be granted for 12 months.
2. The following quantity limits apply:

Eucriisa	60 gam per 30 days
----------	--------------------

## References

1. Eucriisa Ointment 2% (crisaborole) [prescribing information]. New York, NY: Pfizer Labs; April 2020
2. Paller AS, Tom WL, Lebwohl MG et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. *J Am Acad Dermatol*. 2016; 75(3):494-503.e4
3. Misery L, Belloni Fortina A, El Hachem M, et al. A position paper on the management of itch and pain in atopic dermatitis from the International Society of Atopic Dermatitis (ISAD)/Oriented Patient-Education Network in Dermatology (OPENED) task force. *J Eur Acad Dermatol Venereol* 2021; 35:787
4. Sigurgeirsson B, Boznanski A, Todd G, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. *Pediatrics* 2015; 135:597.
5. Eichenfield LF, Call RS, Forsha DW, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. *J Am Acad Dermatol* 2017; 77:641.
6. Svensson A, Chambers C, Gånemo A, Mitchell SA. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. *Curr Med Res Opin* 2011; 27:1395
7. Li AW, Yin ES, Antaya RJ. Topical Corticosteroid Phobia in Atopic Dermatitis: A Systematic Review. *JAMA Dermatol* 2017; 153:1036
8. Choi JY, Dawe R, Ibbotson S, et al. Quantitative analysis of topical treatments in atopic dermatitis: unexpectedly low use of emollients and strong correlation of topical corticosteroid use both with depression and concurrent asthma. *Br J Dermatol* 2020; 182:1017

## Review History

07/21/2021- Reviewed at July P&T; Switched from CVS Standard criteria to AllWays Health Partners custom template. Effective 10/01/2021.

## Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.